SNU Cell Lines in Immunotherapy Biomarker Discovery

SNU Cell Lines in Immunotherapy Biomarker Discovery

The identification of reliable biomarkers remains one of the most significant challenges in immunotherapy development. Seoul National University (SNU) cell lines, derived from Korean gastric and colorectal cancer patients, have emerged as invaluable tools for biomarker discovery due to their well-characterized genetic profiles, diverse mutation landscapes, and documented responses to immunomodulatory agents. These cell lines provide researchers with clinically relevant models that bridge the gap between laboratory findings and patient outcomes, enabling the systematic identification of predictive markers for immunotherapy response.

Key Takeaways

• SNU cell lines offer genetically diverse models representing Asian patient populations in immunotherapy research
• These cell lines express variable levels of PD-L1, MSI status, and tumor mutational burden critical for checkpoint inhibitor studies
• SNU gastric cancer models enable identification of biomarkers predicting response to anti-PD-1/PD-L1 therapy
• Integrated genomic and proteomic profiling of SNU lines reveals novel immunotherapy targets
• SNU cell line panels facilitate high-throughput screening for immune checkpoint expression patterns

Published: 2023  |  Last reviewed: May 2026

Genetic Diversity of SNU Cell Lines for Immunotherapy Modeling

The SNU cell line collection represents a genetically heterogeneous panel that captures the molecular diversity observed in Asian gastric and colorectal cancer patient populations. Established at Seoul National University Hospital, these cell lines harbor distinct mutation profiles spanning oncogenes, tumor suppressors, and DNA repair pathway genes. This genetic diversity is essential for immunotherapy biomarker research, as it enables systematic correlation between specific genomic alterations and immunotherapy response patterns.

SNU gastric cancer cell lines exhibit variable microsatellite instability (MSI) status, a critical determinant of checkpoint inhibitor efficacy. MSI-high tumors demonstrate enhanced neoantigen production and immune cell infiltration, making MSI status a validated biomarker for anti-PD-1 therapy in gastric cancer. The availability of both MSI-high and microsatellite stable (MSS) SNU cell lines enables comparative studies that elucidate the mechanistic basis for differential immunotherapy responses.

For comprehensive gastric cancer research, researchers frequently utilize cell models such as AGS Cells alongside SNU lines to establish comparative panels. The KATO-III Cells provide additional diffuse-type gastric cancer representation, while MKN-45 Cells and MKN-74 Cells contribute intestinal-type gastric adenocarcinoma models.

PD-L1 Expression Profiling in SNU Cell Lines

Programmed death-ligand 1 (PD-L1) expression serves as a cornerstone biomarker in immunotherapy patient selection. SNU cell lines demonstrate variable constitutive and inducible PD-L1 expression levels, providing researchers with models spanning the full spectrum of PD-L1 positivity observed clinically. This variability enables mechanistic studies investigating the regulation of PD-L1 expression and its correlation with response to checkpoint blockade.

Interferon-gamma (IFN-γ) stimulation of SNU cell lines reveals distinct PD-L1 induction patterns that correlate with upstream JAK-STAT pathway integrity. Cell lines harboring JAK1/2 mutations exhibit impaired PD-L1 upregulation following IFN-γ exposure, modeling a resistance mechanism observed in immunotherapy-refractory patients. This phenotype enables screening for combination strategies that overcome PD-L1 induction defects.

The immunological investigation of tumor-immune interactions requires appropriate immune cell models. THP-1 Cells serve as monocyte/macrophage models for co-culture studies assessing tumor cell-immune cell crosstalk. Jurkat E6.1 Cells provide T-cell models for evaluating checkpoint inhibitor effects on T-cell activation in the presence of PD-L1-expressing tumor cells.

Tumor Mutational Burden Assessment Using SNU Panels

Tumor mutational burden (TMB) has emerged as a predictive biomarker for immunotherapy response across multiple tumor types. SNU cell lines spanning low, intermediate, and high TMB categories enable systematic evaluation of the relationship between mutation load and immunogenicity. Whole-exome sequencing of SNU panels has established reference TMB values that facilitate comparison with clinical samples.

High-TMB SNU cell lines generate abundant predicted neoantigens capable of eliciting T-cell responses. Neoantigen prediction algorithms applied to SNU genomic data identify candidate epitopes for validation studies assessing T-cell recognition. This approach enables identification of immunogenic mutations that may serve as therapeutic targets for personalized neoantigen vaccines or adoptive cell therapies.

The correlation between TMB and checkpoint inhibitor response in SNU cell lines has been validated through in vitro co-culture assays and in vivo studies using immunocompetent mouse models. K562 Cells serve as target cells for natural killer cell cytotoxicity assays that complement T-cell studies, while HL-60 Cells provide myeloid lineage models for investigating the tumor microenvironment.

Published: 2023  |  Last reviewed: May 2026

Integrated Genomic and Proteomic Biomarker Discovery

Multi-omic profiling of SNU cell lines reveals biomarker candidates beyond established markers such as PD-L1 and MSI status. Transcriptomic analysis identifies gene expression signatures associated with T-cell exclusion, interferon response, and epithelial-mesenchymal transition that predict immunotherapy outcomes. These signatures enable patient stratification strategies that improve upon single-marker approaches.

Proteomic profiling of SNU cell lines quantifies surface immunomodulatory molecules including additional checkpoint receptors (TIM-3, LAG-3, TIGIT), co-stimulatory molecules (CD80, CD86, ICOS-L), and antigen presentation machinery components. This comprehensive surface immunome characterization identifies combination immunotherapy targets and predicts sensitivity to emerging checkpoint inhibitors.

Cell culture optimization requires appropriate media formulations. RPMI 1640 Medium provides standard culture conditions for lymphocyte-based assays, while DMEM supports epithelial cancer cell line maintenance. Proper cryopreservation with Freeze Medium CM-1 ensures cell line integrity across experimental timelines.

High-Throughput Screening for Checkpoint Expression Patterns

The SNU cell line panel enables scalable screening approaches to identify checkpoint expression patterns predictive of immunotherapy response. Automated flow cytometry and high-content imaging platforms quantify multiple checkpoint molecules simultaneously across the SNU panel, generating comprehensive immunophenotypic datasets amenable to machine learning analysis.

CRISPR-based genetic screens in SNU cell lines identify genes required for checkpoint expression and immune evasion. Genome-wide loss-of-function screens reveal novel regulators of PD-L1 expression and antigen presentation that represent therapeutic targets for immunotherapy sensitization. These genetic dependencies can be validated using pharmacological approaches with existing compounds.

For gastrointestinal cancer research beyond gastric models, colorectal cancer cell lines expand screening capabilities. HCT116 Cells provide MSI-high colorectal cancer models, while Caco-2 Cells and DLD-1 Cells represent additional colorectal adenocarcinoma models with distinct genetic backgrounds. SW620 Cells derived from metastatic disease enable investigation of immunotherapy in the metastatic setting.

Clinical Translation of SNU-Derived Biomarkers

Biomarker candidates identified in SNU cell lines require rigorous validation in clinical cohorts before translation to patient care. Retrospective analysis of SNU-derived biomarkers in immunotherapy clinical trial samples establishes predictive accuracy and identifies optimal cutoff values. This validation process prioritizes biomarkers with robust performance across diverse patient populations.

The SNU cell line collection has contributed to the identification of biomarkers currently under clinical evaluation. These include gene expression signatures predicting checkpoint inhibitor response, circulating biomarkers detectable in patient blood samples, and imaging biomarkers assessable through non-invasive modalities. Prospective clinical trials incorporating SNU-derived biomarkers are advancing through development pipelines.

Quality assurance in biomarker discovery requires authenticated cell lines and standardized protocols. Cell line authentication services verify cell line identity through STR profiling, while Mycoplasma testing ensures culture integrity. These quality control measures are essential for generating reproducible biomarker data suitable for regulatory submission.

Conclusion

SNU cell lines provide essential tools for immunotherapy biomarker discovery, offering genetically diverse models that capture the molecular heterogeneity of Asian gastric and colorectal cancer patient populations. Through systematic profiling of PD-L1 expression, MSI status, tumor mutational burden, and multi-omic biomarkers, researchers can identify predictive markers that improve patient selection for immunotherapy. The continued expansion of SNU cell line characterization and validation of SNU-derived biomarkers in clinical cohorts will accelerate the translation of laboratory discoveries to improved patient outcomes.